Premium
Implementation of Antenatal Prophylaxis: A Midwife’s Perspective
Author(s) -
Kyriakopoulos Vickie
Publication year - 2005
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.2005.00554ab.x
Subject(s) - medicine , officer , haemolytic disease , perspective (graphical) , best practice , nursing , obstetrics , family medicine , pregnancy , management , political science , fetus , artificial intelligence , biology , computer science , law , economics , genetics
In July 2003, The Royal Women’s Hospital, Melbourne implemented the use of Prophylactic Rh D Immunoglobulin in obstetrics to help reduce the incidence of Haemolytic Disease of the Newborn (HDN), as recommended by the Chief Medical Officer in December 2002. Successful implementation required the coordinated efforts of a large working party including haematologists, laboratory staff, blood bank, product technicians, CSL, clinical managers, midwives, obstetricians, clerical staff and educators. New practice guidelines, system processes, procedures and staff education needed to be developed and coordinated to support the successful implementation across the Royal Women’s Hospital complex maternity care programme sites. This talk firstly outlines how this implementation was achieved across a complex organisation as is The Royal Women’s Hospital, and the tools that were invaluable in contributing to its consistent success. Examples of materials developed to support staff, from discussion guidelines to materials developed to aid pregnant women to make an informed choice will be shown. The second part of this talk offers an insight into the concerns that pregnant women raise regarding the offering of prophylactic Anti – D, from a midwifery perspective. What does the consumer think and how can we best serve their needs? What are the practical considerations that help Rh D negative women choose what is best for themselves and their babies? It is hoped that this talk contributes practical information to anyone involved in the delivery of prophylactic Anti‐D to pregnant women for the prevention of HDN.